Latest news:
FDA Announces Shift Away from Mandatory Animal Testing – BioReperia Offers a Validated, Human-Relevant Alternative
Read more
Screening

An agile & highly customizable
toolbox for drug screening

Our unique ZTX®platform is shortening the time for drug discovery by providing in-vivo data on tumor regression and metastasis inhibition of compounds within 5 days.

Cell line screening

Screening many CDX models to find a new indication for your drug

Test a variety of cell lines derived from tumors from different anatomical locations to screen alternative indications to achieve the highest therapeutic potential.

Screening a panel of 12 tumor cell lines identifies new indications for a drug targeting hypoxia-induced tumor metabolism

Patient stratification

Use ZTX® as an inclusion criteria in your clinical trial

patient stratification clinical trial

How it works

  • Patient tumor cells are tested in the ZTX®platform for their sensitivity toward a specific treatment/treatment combination
  • Identification of patient characteristics for responders and non-responders
  • Include only patients who respond to the drug candidate in the clinical trial

Output

  • Stratification into likely sensitive subtypes for a specific treatment to be used as inclusion criteria for more efficient clinical trial planning
  • Tool for stratification of patients for clinical trial, increasing the chances of positive outcomes in the clinical trial
  • Reduce the number of patients needed in each treatment arm and save both time and costs
pdx efficacy paclitaxel

Screen models for your next mouse PDX study

Test anti-tumor and anti-metastatic drug efficacy in a large number of PDX models to select those with the best chance for success in subsequent mouse studies.

Read more
Screening of Antibody-Drug-conjugates

Identify the lead ADC candidate with the strongest tumor-targeting efficacy and minimal toxicity

The ZTX® is an excellent platform for screening antibody-drug conjugates (ADCs) due to its suitability to evaluate biodistribution and tumor targeting effect of ADCs through intravenous administration. Compare novel ADCs against standard-of-care treatment to demonstrate superior efficacy.

The ZTX® platform is also particularly well-suited for compounds that function through immune activation. Since the zebrafish larva lacks an endogenous immune system, a human immune system can be readily reconstituted to study these mechanisms of action

Learn more

This website uses cookies

We use essential cookies to make our website work. With your consent, we also use non-essential cookies to improve the user experience and analyze website traffic. You can change your cookie settings at any time by clicking on Cookie settings..

Which cookies do you want to accept?

This website uses cookies

We use different types of cookies to optimize your experience on our website. Click on the categories below to learn more about their purposes. You can choose which types of cookies to allow and can change your settings at any time. Remember that disabling cookies may affect your experience on the website.

Which cookies do you want to accept?

These cookies are essential for the proper functioning of the website and cannot be disabled.

These cookies collect information about how you use our website. All of the data is anonymized and cannot be used to identify you.

Read more about Google's privacy policy and terms of use